The FDA approved ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist, for moderate to severe plaque psoriasis in patients aged 12 and older who weigh at least 40 kg. Johnson & Johnson will commercialize ICOTYDE under its agreement with Protagonist. The approval triggered a USD 50 million milestone payment to Protagonist. Protagonist is eligible for tiered royalties of 6% to 10% on global net sales and up to USD 580 million in additional milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603180805ACCESSWRNAPR_____1148778) on March 18, 2026, and is solely responsible for the information contained therein.